Immuron ceo, steven lydeamore to present at coffee microcaps

Melbourne, australia, may 02, 2023 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), an australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to provide a copy of the presentation being made today in melbourne at coffee microcaps conference by our chief executive officer, steven lydeamore.
IMRN Ratings Summary
IMRN Quant Ranking